0 XP   0   0   0

AstraZeneca Pharma India Limited
Buy, Hold or Sell?

Should you buy, hold or sell Astrazeneca?

I guess you are interested in AstraZeneca Pharma India Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Astrazeneca

Let's start. I'm going to help you getting a better view of AstraZeneca Pharma India Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is AstraZeneca Pharma India Limited even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how AstraZeneca Pharma India Limited is doing in the market. If the company is worth buying. The latest step is to find out how other investors value AstraZeneca Pharma India Limited. The closing price on 2023-02-03 was INR3,308 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
AstraZeneca Pharma India Limited Daily Candlestick Chart
AstraZeneca Pharma India Limited Daily Candlestick Chart
Summary









1. Valuation of Astrazeneca




Current price per share

INR3,308.35

2. Growth of Astrazeneca




Is Astrazeneca growing?

Current yearPrevious yearGrowGrow %
How rich?$61.8m$55.1m$6.6m10.8%

How much money is Astrazeneca making?

Current yearPrevious yearGrowGrow %
Making money$7.4m$11.2m-$3.8m-51.5%
Net Profit Margin7.6%11.5%--

How much money comes from the company's main activities?

3. Financial Health of Astrazeneca




Comparing to competitors in the Drug Manufacturers - Major industry




  Industry Rankings (Drug Manufacturers - Major)  



Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of AstraZeneca Pharma India Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Astrazeneca earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Astrazeneca to the Drug Manufacturers - Major industry mean.
  • A Net Profit Margin of 7.6% means that ₹0.08 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of AstraZeneca Pharma India Limited:

  • The MRQ is 7.6%. The company is making a profit. +1
  • The TTM is 7.6%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ7.6%TTM7.6%0.0%
TTM7.6%YOY11.5%-3.8%
TTM7.6%5Y8.0%-0.3%
5Y8.0%10Y4.4%+3.5%
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ7.6%10.8%-3.2%
TTM7.6%10.8%-3.2%
YOY11.5%14.8%-3.3%
5Y8.0%12.2%-4.2%
10Y4.4%11.9%-7.5%
1.1.2. Return on Assets

Shows how efficient Astrazeneca is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Astrazeneca to the Drug Manufacturers - Major industry mean.
  • 7.2% Return on Assets means that Astrazeneca generated ₹0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of AstraZeneca Pharma India Limited:

  • The MRQ is 7.2%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 7.2%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ7.2%TTM7.2%0.0%
TTM7.2%YOY12.0%-4.9%
TTM7.2%5Y9.0%-1.8%
5Y9.0%10Y5.1%+3.9%
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ7.2%1.8%+5.4%
TTM7.2%2.3%+4.9%
YOY12.0%3.0%+9.0%
5Y9.0%3.0%+6.0%
10Y5.1%2.7%+2.4%
1.1.3. Return on Equity

Shows how efficient Astrazeneca is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Astrazeneca to the Drug Manufacturers - Major industry mean.
  • 12.0% Return on Equity means Astrazeneca generated ₹0.12 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of AstraZeneca Pharma India Limited:

  • The MRQ is 12.0%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 12.0%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ12.0%TTM12.0%0.0%
TTM12.0%YOY20.5%-8.4%
TTM12.0%5Y16.2%-4.1%
5Y16.2%10Y8.7%+7.5%
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ12.0%2.5%+9.5%
TTM12.0%3.9%+8.1%
YOY20.5%4.4%+16.1%
5Y16.2%4.2%+12.0%
10Y8.7%4.0%+4.7%

1.2. Operating Efficiency of AstraZeneca Pharma India Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Astrazeneca is operating .

  • Measures how much profit Astrazeneca makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Astrazeneca to the Drug Manufacturers - Major industry mean.
  • An Operating Margin of 0.0% means the company generated ₹0.00  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of AstraZeneca Pharma India Limited:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y6.9%-6.9%
5Y6.9%10Y3.3%+3.6%
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ-29.7%-29.7%
TTM-11.5%-11.5%
YOY-11.7%-11.7%
5Y6.9%12.0%-5.1%
10Y3.3%11.0%-7.7%
1.2.2. Operating Ratio

Measures how efficient Astrazeneca is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Major industry mean).
  • An Operation Ratio of 0.45 means that the operating costs are ₹0.45 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of AstraZeneca Pharma India Limited:

  • The MRQ is 0.454. The company is very efficient in keeping operating costs low. +2
  • The TTM is 0.454. The company is very efficient in keeping operating costs low. +2
Trends
Current periodCompared to+/- 
MRQ0.454TTM0.4540.000
TTM0.454YOY0.415+0.038
TTM0.4545Y0.961-0.508
5Y0.96110Y1.163-0.201
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4540.475-0.021
TTM0.4540.425+0.029
YOY0.4150.731-0.316
5Y0.9610.943+0.018
10Y1.1630.983+0.180

1.3. Liquidity of AstraZeneca Pharma India Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Astrazeneca is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Major industry mean).
  • A Current Ratio of 2.12 means the company has ₹2.12 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of AstraZeneca Pharma India Limited:

  • The MRQ is 2.121. The company is able to pay all its short-term debts. +1
  • The TTM is 2.121. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.121TTM2.1210.000
TTM2.121YOY2.039+0.083
TTM2.1215Y1.786+0.335
5Y1.78610Y1.499+0.288
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ2.1211.824+0.297
TTM2.1211.800+0.321
YOY2.0391.807+0.232
5Y1.7861.305+0.481
10Y1.4991.218+0.281
1.3.2. Quick Ratio

Measures if Astrazeneca is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Astrazeneca to the Drug Manufacturers - Major industry mean.
  • A Quick Ratio of 1.61 means the company can pay off ₹1.61 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of AstraZeneca Pharma India Limited:

  • The MRQ is 1.607. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.607. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.607TTM1.6070.000
TTM1.607YOY1.442+0.165
TTM1.6075Y1.299+0.308
5Y1.29910Y0.969+0.330
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6071.248+0.359
TTM1.6071.200+0.407
YOY1.4421.151+0.291
5Y1.2990.836+0.463
10Y0.9690.750+0.219

1.4. Solvency of AstraZeneca Pharma India Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Astrazeneca assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Astrazeneca to Drug Manufacturers - Major industry mean.
  • A Debt to Asset Ratio of 0.40 means that Astrazeneca assets are financed with 40.3% credit (debt) and the remaining percentage (100% - 40.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of AstraZeneca Pharma India Limited:

  • The MRQ is 0.403. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.403. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.403TTM0.4030.000
TTM0.403YOY0.411-0.008
TTM0.4035Y0.445-0.042
5Y0.44510Y0.495-0.050
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4030.415-0.012
TTM0.4030.419-0.016
YOY0.4110.429-0.018
5Y0.4450.455-0.010
10Y0.4950.431+0.064
1.4.2. Debt to Equity Ratio

Measures if Astrazeneca is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Astrazeneca to the Drug Manufacturers - Major industry mean.
  • A Debt to Equity ratio of 67.5% means that company has ₹0.67 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of AstraZeneca Pharma India Limited:

  • The MRQ is 0.675. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.675. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.675TTM0.6750.000
TTM0.675YOY0.698-0.023
TTM0.6755Y0.809-0.134
5Y0.80910Y1.030-0.221
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6750.6750.000
TTM0.6750.698-0.023
YOY0.6980.738-0.040
5Y0.8090.840-0.031
10Y1.0300.814+0.216

2. Market Valuation of AstraZeneca Pharma India Limited

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Astrazeneca generates.

  • Above 15 is considered overpriced but always compare Astrazeneca to the Drug Manufacturers - Major industry mean.
  • A PE ratio of 103.71 means the investor is paying ₹103.71 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of AstraZeneca Pharma India Limited:

  • The EOD is 134.267. Seems overpriced? -1
  • The MRQ is 103.711. Seems overpriced? -1
  • The TTM is 103.711. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD134.267MRQ103.711+30.556
MRQ103.711TTM103.7110.000
TTM103.711YOY80.659+23.052
TTM103.7115Y89.663+14.049
5Y89.66310Y-490.822+580.485
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
EOD134.26773.229+61.038
MRQ103.71166.328+37.383
TTM103.71160.797+42.914
YOY80.65933.289+47.370
5Y89.66360.412+29.251
10Y-490.82264.422-555.244
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Astrazeneca.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of AstraZeneca Pharma India Limited:

  • The MRQ is 157.082. Seems overpriced? -1
  • The TTM is 157.082. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ157.082TTM157.0820.000
TTM157.082YOY62.427+94.656
TTM157.0825Y78.956+78.127
5Y78.95610Y84.061-5.105
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ157.082-0.235+157.317
TTM157.0820.137+156.945
YOY62.4270.124+62.303
5Y78.9560.232+78.724
10Y84.0610.222+83.839

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Astrazeneca is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Major industry mean).
  • A PB ratio of 12.49 means the investor is paying ₹12.49 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of AstraZeneca Pharma India Limited:

  • The EOD is 16.173. Seems overpriced? -1
  • The MRQ is 12.493. Seems overpriced? -1
  • The TTM is 12.493. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD16.173MRQ12.493+3.681
MRQ12.493TTM12.4930.000
TTM12.493YOY16.497-4.004
TTM12.4935Y14.277-1.784
5Y14.27710Y14.160+0.116
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
EOD16.1731.495+14.678
MRQ12.4931.439+11.054
TTM12.4931.890+10.603
YOY16.4972.460+14.037
5Y14.2771.972+12.305
10Y14.1602.221+11.939
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of AstraZeneca Pharma India Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--22.08822.0880%36.692-40%23.082-4%22.728-3%
Book Value Growth--1.1211.1210%1.252-10%1.182-5%1.154-3%
Book Value Per Share--204.556204.5560%182.468+12%150.378+36%116.820+75%
Book Value Per Share Growth--1.1211.1210%1.252-10%1.182-5%1.154-3%
Current Ratio--2.1212.1210%2.039+4%1.786+19%1.499+42%
Debt To Asset Ratio--0.4030.4030%0.411-2%0.445-10%0.495-19%
Debt To Equity Ratio--0.6750.6750%0.698-3%0.809-17%1.030-34%
Dividend Per Share--2.0002.0000%2.0000%1.000+100%0.556+260%
Dividend Per Share Growth--1.0001.0000%2.000-50%1.500-33%1.500-33%
Eps--24.64024.6400%37.320-34%24.598+0%13.841+78%
Eps Growth--0.6600.6600%1.292-49%1.334-51%-3.276+596%
Free Cash Flow Per Share--36.47236.4720%38.828-6%24.020+52%12.831+184%
Free Cash Flow Per Share Growth--0.9390.9390%1.326-29%3.764-75%2.636-64%
Free Cash Flow To Equity Per Share--32.68832.6880%35.240-7%22.037+48%15.506+111%
Free Cash Flow To Equity Per Share Growth--0.9280.9280%1.318-30%3.725-75%2.610-64%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--798.143--------
Intrinsic Value_10Y_min--669.913--------
Intrinsic Value_1Y_max--45.955--------
Intrinsic Value_1Y_min--44.654--------
Intrinsic Value_3Y_max--164.007--------
Intrinsic Value_3Y_min--154.430--------
Intrinsic Value_5Y_max--313.322--------
Intrinsic Value_5Y_min--285.570--------
Net Profit Margin--0.0760.0760%0.115-33%0.080-4%0.044+73%
Operating Margin----0%-0%0.069-100%0.033-100%
Operating Ratio--0.4540.4540%0.415+9%0.961-53%1.163-61%
Pb Ratio16.173+23%12.49312.4930%16.497-24%14.277-12%14.160-12%
Pe Ratio134.267+23%103.711103.7110%80.659+29%89.663+16%-490.822+573%
Peg Ratio--157.082157.0820%62.427+152%78.956+99%84.061+87%
Price Per Share3308.350+23%2555.4502555.4500%3010.200-15%2176.400+17%1666.750+53%
Price To Total Gains Ratio137.344+23%106.088106.0880%77.799+36%92.658+14%60.610+75%
Profit Growth--0.6600.6600%1.292-49%1.334-51%-3.276+596%
Quick Ratio--1.6071.6070%1.442+11%1.299+24%0.969+66%
Return On Assets--0.0720.0720%0.120-40%0.090-20%0.051+42%
Return On Equity--0.1200.1200%0.205-41%0.162-26%0.087+38%
Revenue Growth--0.9900.9900%0.978+1%1.085-9%1.074-8%
Total Gains Per Share--24.08824.0880%38.692-38%24.082+0%23.284+3%
Total Gains Per Share Growth--0.6230.6230%1.463-57%1.359-54%1.446-57%
Usd Book Value--61878190.00061878190.0000%55196570.000+12%45489466.000+36%35337920.662+75%
Usd Book Value Change Per Share--0.2670.2670%0.444-40%0.279-4%0.275-3%
Usd Book Value Per Share--2.4752.4750%2.208+12%1.820+36%1.414+75%
Usd Dividend Per Share--0.0240.0240%0.0240%0.012+100%0.007+260%
Usd Eps--0.2980.2980%0.452-34%0.298+0%0.167+78%
Usd Free Cash Flow----0%-0%-0%-0%
Usd Free Cash Flow Per Share--0.4410.4410%0.470-6%0.291+52%0.155+184%
Usd Free Cash Flow To Equity Per Share--0.3960.3960%0.426-7%0.267+48%0.188+111%
Usd Price Per Share40.031+23%30.92130.9210%36.423-15%26.334+17%20.168+53%
Usd Profit--7453600.0007453600.0000%11289300.000-34%7440774.000+0%4187008.176+78%
Usd Revenue--97477600.00097477600.0000%98440760.000-1%90780250.000+7%78064349.383+25%
Usd Total Gains Per Share--0.2910.2910%0.468-38%0.291+0%0.282+3%
 EOD+2 -3MRQTTM+0 -0YOY+11 -275Y+23 -1810Y+28 -13

3.2. Fundamental Score

Let's check the fundamental score of AstraZeneca Pharma India Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15134.267
Price to Book Ratio (EOD)Between0-116.173
Net Profit Margin (MRQ)Greater than00.076
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.607
Current Ratio (MRQ)Greater than12.121
Debt to Asset Ratio (MRQ)Less than10.403
Debt to Equity Ratio (MRQ)Less than10.675
Return on Equity (MRQ)Greater than0.150.120
Return on Assets (MRQ)Greater than0.050.072
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of AstraZeneca Pharma India Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.314
Ma 20Greater thanMa 503,401.740
Ma 50Greater thanMa 1003,371.780
Ma 100Greater thanMa 2003,298.228
OpenGreater thanClose3,369.800
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2022-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets8,565,600
Total Liabilities3,451,700
Total Stockholder Equity5,113,900
 As reported
Total Liabilities 3,451,700
Total Stockholder Equity+ 5,113,900
Total Assets = 8,565,600

Assets

Total Assets8,565,600
Total Current Assets7,056,700
Long-term Assets7,056,700
Total Current Assets
Cash And Cash Equivalents 88,200
Short-term Investments 900
Net Receivables 858,900
Inventory 1,413,200
Other Current Assets 400
Total Current Assets  (as reported)7,056,700
Total Current Assets  (calculated)2,361,600
+/- 4,695,100
Long-term Assets
Property Plant Equipment 766,900
Long-term Assets  (as reported)0
Long-term Assets  (calculated)766,900
+/- 766,900

Liabilities & Shareholders' Equity

Total Current Liabilities3,326,500
Long-term Liabilities-
Total Stockholder Equity5,113,900
Total Current Liabilities
Total Current Liabilities  (as reported)3,326,500
Total Current Liabilities  (calculated)0
+/- 3,326,500
Long-term Liabilities
Long term Debt Total 50,200
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)50,200
+/- 50,200
Total Stockholder Equity
Common Stock50,000
Retained Earnings 5,044,400
Total Stockholder Equity (as reported)5,113,900
Total Stockholder Equity (calculated)5,094,400
+/- 19,500
Other
Cash And Equivalents4,396,000
Cash and Short Term Investments 4,485,100
Common Stock Shares Outstanding 25,000
Liabilities and Stockholders Equity 8,565,600



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-31
> Total Assets 
4,155,875
4,115,928
4,487,300
4,154,900
4,605,400
5,618,000
7,063,600
7,747,100
8,565,600
8,565,6007,747,1007,063,6005,618,0004,605,4004,154,9004,487,3004,115,9284,155,875
   > Total Current Assets 
2,746,243
2,632,605
2,658,400
2,515,500
3,209,200
4,047,200
5,423,200
6,187,600
7,056,700
7,056,7006,187,6005,423,2004,047,2003,209,2002,515,5002,658,4002,632,6052,746,243
       Cash And Cash Equivalents 
890,709
250,844
700,000
1,132,300
1,094,500
1,683,600
818,000
30,100
88,200
88,20030,100818,0001,683,6001,094,5001,132,300700,000250,844890,709
       Short-term Investments 
0
0
0
6,100
116,800
0
1,690,000
0
900
90001,690,0000116,8006,100000
       Net Receivables 
605,090
1,259,771
823,400
430,000
546,300
797,500
832,100
851,900
858,900
858,900851,900832,100797,500546,300430,000823,4001,259,771605,090
       Inventory 
973,484
870,977
783,000
589,100
1,142,600
1,192,100
1,663,100
1,601,800
1,413,200
1,413,2001,601,8001,663,1001,192,1001,142,600589,100783,000870,977973,484
       Other Current Assets 
276,961
251,013
6,300
4,200
2,600
600
200
100
400
4001002006002,6004,2006,300251,013276,961
   > Long-term Assets 
0
0
0
1,249,758
1,396,200
1,570,800
1,640,400
0
0
001,640,4001,570,8001,396,2001,249,758000
       Property Plant Equipment 
1,035,309
1,131,941
1,036,600
916,500
790,300
817,300
957,700
849,800
766,900
766,900849,800957,700817,300790,300916,5001,036,6001,131,9411,035,309
       Long Term Investments 
5
5
5
0
0
0
0
0
0
000000555
       Long-term Assets Other 
0
0
0
6,055
6,000
6,000
-1,158,400
0
0
00-1,158,4006,0006,0006,055000
> Total Liabilities 
2,439,924
2,608,375
2,452,400
1,926,200
2,136,100
2,610,000
3,419,200
3,185,400
3,451,700
3,451,7003,185,4003,419,2002,610,0002,136,1001,926,2002,452,4002,608,3752,439,924
   > Total Current Liabilities 
2,435,031
2,598,185
2,430,800
1,903,400
2,069,500
2,589,800
3,272,400
3,035,000
3,326,500
3,326,5003,035,0003,272,4002,589,8002,069,5001,903,4002,430,8002,598,1852,435,031
       Short-term Debt 
0
6,061
0
0
0
0
0
0
0
00000006,0610
       Short Long Term Debt 
0
6,061
0
0
0
0
0
0
0
00000006,0610
       Accounts payable 
1,098,710
1,112,716
946,284
357,704
1,272,000
1,682,000
2,097,200
0
0
002,097,2001,682,0001,272,000357,704946,2841,112,7161,098,710
       Other Current Liabilities 
420,538
405,729
306,849
279,118
229,500
219,200
196,200
0
0
00196,200219,200229,500279,118306,849405,729420,538
   > Long-term Liabilities 
0
0
0
124,202
66,600
20,200
146,800
0
0
00146,80020,20066,600124,202000
       Long term Debt Total 
0
0
0
0
0
0
93,000
86,300
50,200
50,20086,30093,000000000
       Capital Lease Obligations Min Short Term Debt
0
-6,061
0
0
0
0
118,400
0
0
00118,4000000-6,0610
       Long-term Liabilities Other 
0
0
0
15,149
0
0
0
0
0
0000015,149000
> Total Stockholder Equity
1,715,950
1,507,553
2,034,900
2,228,700
2,469,300
3,008,000
3,644,400
4,561,700
5,113,900
5,113,9004,561,7003,644,4003,008,0002,469,3002,228,7002,034,9001,507,5531,715,950
   Common Stock
50,000
50,000
50,000
50,000
50,000
50,000
50,000
50,000
50,000
50,00050,00050,00050,00050,00050,00050,00050,00050,000
   Retained Earnings 
942,440
734,043
1,972,200
2,162,200
2,398,500
2,937,000
3,578,500
4,495,800
5,044,400
5,044,4004,495,8003,578,5002,937,0002,398,5002,162,2001,972,200734,043942,440
   Capital Surplus 000000000
   Treasury Stock000000000
   Other Stockholders Equity 
723,510
723,510
723,510
723,510
744,300
744,500
739,400
0
0
00739,400744,500744,300723,510723,510723,510723,510



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2022-03-31)

Gross Profit (+$)
totalRevenue8,056,000
Cost of Revenue-3,655,600
Gross Profit4,400,4004,400,400
 
Operating Income (+$)
Gross Profit4,400,400
Operating Expense--
Operating Income693,6004,400,400
 
Operating Expense (+$)
Research Development-
Selling General Administrative3,436,400
Selling And Marketing Expenses-
Operating Expense-3,436,400
 
Net Interest Income (+$)
Interest Income104,000
Interest Expense--
Net Interest Income-104,000
 
Pretax Income (+$)
Operating Income693,600
Net Interest Income-
Other Non-Operating Income Expenses-
Income Before Tax (EBT)830,400693,600
EBIT - interestExpense = 0
616,000
616,000
Interest Expense-
Earnings Before Interest and Taxes (ebit)-830,400
Earnings Before Interest and Taxes (ebitda)-
 
After tax Income (+$)
Income Before Tax830,400
Tax Provision-214,400
Net Income From Continuing Ops-616,000
Net Income616,000
Net Income Applicable To Common Shares616,000
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-0
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
TM4C.F
2 minutes ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of TM4C.F.

TM4C.F Daily Candlestick Chart
TMV.F
2 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of TMV.F.

TMV.F Daily Candlestick Chart
TL01.F
2 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TL01.F.

TL01.F Daily Candlestick Chart
TCA.F
5 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of TCA.F.

TCA.F Daily Candlestick Chart
T5O.F
5 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of T5O.F.

T5O.F Daily Candlestick Chart
T0J.F
7 minutes ago

I found you a Golden Cross on the daily chart of T0J.F.

T0J.F Daily Candlestick Chart
SSU.F
9 minutes ago

I found you a Golden Cross on the daily chart of SSU.F.

SSU.F Daily Candlestick Chart
SND.F
11 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SND.F.

SND.F Daily Candlestick Chart
JEDI.XETRA
11 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of JEDI.XETRA.

JEDI.XETRA Daily Candlestick Chart
PANR.LSE
11 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of PANR.LSE.

PANR.LSE Daily Candlestick Chart
XFRM.LSE
12 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of XFRM.LSE.

XFRM.LSE Daily Candlestick Chart
XB0T.XETRA
12 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XB0T.XETRA.

XB0T.XETRA Daily Candlestick Chart
WAXG.XETRA
12 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of WAXG.XETRA.

WAXG.XETRA Daily Candlestick Chart
UIMS.XETRA
12 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of UIMS.XETRA.

UIMS.XETRA Daily Candlestick Chart
LGGA.XETRA
12 minutes ago

I found you a Golden Cross on the daily chart of LGGA.XETRA.

LGGA.XETRA Daily Candlestick Chart
XDUS.LSE
13 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XDUS.LSE.

XDUS.LSE Daily Candlestick Chart
FLXP.XETRA
13 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of FLXP.XETRA.

FLXP.XETRA Daily Candlestick Chart
XEPA.XETRA
13 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XEPA.XETRA.

XEPA.XETRA Daily Candlestick Chart
V3YL.XETRA
14 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of V3YL.XETRA.

V3YL.XETRA Daily Candlestick Chart
V3YA.XETRA
14 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of V3YA.XETRA.

V3YA.XETRA Daily Candlestick Chart
V3DA.XETRA
14 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of V3DA.XETRA.

V3DA.XETRA Daily Candlestick Chart
V3DL.XETRA
14 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of V3DL.XETRA.

V3DL.XETRA Daily Candlestick Chart
OP7E.XETRA
14 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of OP7E.XETRA.

OP7E.XETRA Daily Candlestick Chart
SUJA.LSE
15 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SUJA.LSE.

SUJA.LSE Daily Candlestick Chart
SUJS.LSE
15 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SUJS.LSE.

SUJS.LSE Daily Candlestick Chart